CRPC is defined as cancer that progresses despite effective suppression of testosterone below castrate levels (≤50 ng/dL) and encompasses a broad spectrum, from an asymptomatic localized disease where the only sign of progression is an elevated prostate-specific antigen (PSA) to rapidly progressive metastatic disease that leads to death. The gene discussed is KLK3; the disease is metastatic neoplasm.